Clinical Trials Logo

Filter by:
NCT ID: NCT00323661 Completed - Clinical trials for Cardiac Pacing, Artificial

Closed Loop Stimulation, Cognitive Performance, and Quality of Life in Pacemaker Patients

COGNITION
Start date: May 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the influence of accelerometer-based rate adaptation and Closed Loop Stimulation on cognitive performance and quality of life in pacemaker patients.

NCT ID: NCT00321919 Completed - Anemia Clinical Trials

A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Start date: July 2000
Phase: Phase 3
Study type: Interventional

This study will evaluate whether anemia prevention with NeoRecormon has an additional impact on reducing cardiovascular risk over conventional anemia treatment in patients mostly with stage IV chronic kidney disease and renal anemia. The anticipated time on study treatment is 2+ years and the target sample size is 500+ individuals.

NCT ID: NCT00321854 Completed - Parkinson Disease Clinical Trials

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Start date: May 2006
Phase: Phase 4
Study type: Interventional

This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease

NCT ID: NCT00321412 Completed - Clinical trials for Inflammatory Bowel Disease

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Start date: March 2006
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with mild to moderately severe Crohn's disease who have fistulas. The study will test whether or not patients receiving AST-120 experience a greater reduction in number of draining fistulas and improvement of their other Crohn's disease symptoms versus patients who receive placebo (material that does not contain any active medication).

NCT ID: NCT00320385 Completed - Neoplasms, Breast Clinical Trials

Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer

Start date: November 2005
Phase: Phase 3
Study type: Interventional

This study will evaluate and compare the safety and efficacy of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with HER2-positive metastatic breast cancer.

NCT ID: NCT00320359 Completed - Clinical trials for Lung Cancer, Small Cell

Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer

Start date: August 2002
Phase: Phase 3
Study type: Interventional

Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer

NCT ID: NCT00319696 Completed - Digital Ulcers Clinical Trials

Bosentan in Digital Ulcers

RAPIDS 2 OL
Start date: July 8, 2004
Phase: Phase 3
Study type: Interventional

The aim of the study is to collect long-term efficacy, tolerability and safety data of bosentan in Systemic Sclerosis (SSc) patients suffering from ischemic digital ulcers (DUs).

NCT ID: NCT00319111 Completed - Clinical trials for Pulmonary Hypertension

Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

BENEFIT OL
Start date: January 2006
Phase: Phase 3
Study type: Interventional

The present trial investigates the long-term safety, tolerability and efficacy of bosentan in patients with inoperable CTEPH.

NCT ID: NCT00317486 Completed - Clinical trials for Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology

Start date: September 2003
Phase: Phase 4
Study type: Interventional

This study evaluates the effects of bosentan on oxygen saturation, hemodynamics and exercise capacity in patients with pulmonary arterial hypertension related to Eisenmenger physiology. Patients receive bosentan or placebo for 16 weeks.

NCT ID: NCT00317395 Completed - Coronary Disease Clinical Trials

Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome

SEPIA-ACS1
Start date: June 2006
Phase: Phase 2
Study type: Interventional

Primary objective: To demonstrate the clinical efficacy of otamixaban (dose effect via 5 intravenous [IV] regimens) in patients with moderate-to-high-risk non-ST elevation acute coronary syndromes (ACS) and planned early invasive strategy. Secondary objectives: To evaluate safety and assess pharmacokinetics (PK) and pharmacodynamics (PD).